Zobrazeno 1 - 10
of 17
pro vyhledávání: '"John C Woolcott"'
Autor:
David T. Rubin, Leonardo Salese, Mitchell Cohen, Paulo G. Kotze, John C. Woolcott, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Joana Torres, Millie D. Long
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Objective: To assess colectomy incidence rates (IRs) and baseline characteristics for the presence of identified colectomy risk fac
Externí odkaz:
https://doaj.org/article/4f14d6481d204724942026dae5b142a5
Autor:
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 2, Pp 357-373 (2022)
Abstract Introduction This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs. Methods Available data from phase 1, randomi
Externí odkaz:
https://doaj.org/article/636def3d7be64a6abbfb716f2f5fce89
Autor:
David P. Hudesman, Joana Torres, Leonardo Salese, John C. Woolcott, Rajiv Mundayat, Chinyu Su, Mahmoud H. Mosli, Jessica R. Allegretti
Publikováno v:
The Patient - Patient-Centered Outcomes Research. 16:95-103
Autor:
Edward V Loftus, Daniel C Baumgart, Krisztina Gecse, Jami A Kinnucan, Susan B Connelly, Leonardo Salese, Chinyu Su, Kenneth K Kwok, John C Woolcott, Alessandro Armuzzi
Publikováno v:
Inflammatory Bowel Diseases. 29:744-751
Background Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Patients with inflammatory bowel disease are susceptible to Clostridium difficile infection (CDI). Here, we evaluate CDI in the tof
Autor:
Remo Panaccione, Maria T. Abreu, Irina Lazariciu, Rajiv Mundayat, Nervin Lawendy, Leonardo Salese, John C. Woolcott, Bruce E. Sands, María Chaparro
Publikováno v:
Alimentary Pharmacology & Therapeutics. 55:1534-1544
Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Aim:This post hoc analysis evaluated tofacitinib persistence in patients with UC in OCTAVE Open, an open-label, long-term extension study of patients receivin
Autor:
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen
Publikováno v:
Scientia
This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs.Available data from phase 1, randomized phase 2/3/3b/4 clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89bdb9b44ccbbf9afb8ee0ad5bd81dda
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-502143
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-502143
Autor:
William J Sandborn, Alessandro Armuzzi, Giuseppina Liguori, Peter M Irving, Ala I Sharara, Rajiv Mundayat, Nervin Lawendy, John C Woolcott, Silvio Danese
Publikováno v:
Inflammatory Bowel Diseases. 28:1338-1347
Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis. We evaluate baseline characteristics as predictors of sustained response and remission in patients with ulcerative colitis receiving tofacitinib
Autor:
David T. Rubin, Leonardo Salese, Paulo G. Kotze, John C. Woolcott, Chinyu Su, Rajiv Mundayat, Jerome Paulissen, Joana Torres, Millie Long
Publikováno v:
American Journal of Gastroenterology. 117:e696-e697
Autor:
David T. Rubin, Joana Torres, Iris Dotan, Lan Terry Xu, Irene Modesto, John C. Woolcott, Sean Gardiner, Bruce E. Sands
Publikováno v:
American Journal of Gastroenterology. 117:e588-e589
Autor:
Boulos, Haraoui, Majed, Khraishi, Denis, Choquette, Larissa, Lisnevskaia, Michelle, Teo, Cassandra, Kinch, Corina, Galos, Patrice, Roy, David, Gruben, John C, Woolcott, Julie, Vaillancourt, John S, Sampalis, Edward C, Keystone, Latha, Naik
Publikováno v:
Arthritis careresearchREFERENCES.
The Canadian Tofacitinib for Rheumatoid Arthritis Observational (CANTORAL) is the first Canadian prospective, observational study assessing tofacitinib. The objective was to assess effectiveness and safety for moderate to severe rheumatoid arthritis